Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myeloid Reconstitution

Long-term haematological recovery following high-dose chemotherapy with autologous bone marrow transplantation or peripheral stem cell transplantation in patients with solid tumours

Bone Marrow Transplantation volume 27, pages 959–966 (2001)Cite this article

Abstract

Long-term peripheral blood counts and factors influencing long-term trilineage haematological recovery of consecutive patients in a single institution treated with high-dose chemotherapy (HDC) and ABMT or PSCT for solid tumours were examined. Patients with a relapse-free survival of <1 year were included in the analysis (n = 131). Peripheral blood counts were examined 6 months and yearly following transplantation. Median follow-up was 4.1 years (range 1–10+ years). Three years after transplantation 91% of patients had normal white blood counts (WBC), 94% normal haemoglobin (Hb) and 75% normal platelets. Trilineage recovery was complete in 70% (n = 83) at 3 years and 85% (n = 50) at 5 years. Recovery of Hb occurred before WBC and platelet recovery. Approximately 25% of patients displayed an elevated MCV throughout the follow-up period. These long-term results were independent of age, high-dose regimen, number of reinfused stem cells and stem cell source. Double (n = 12) vs single (n = 119) transplantations showed significantly slower trilineage recovery and higher MCV. No secondary graft failure, myelodysplasia or leukaemia was encountered. In conclusion, complete trilineage recovery after HDC followed by ABMT or PSCT occurs slowly. PSCT and ABMT are capable of maintaining long-term haematopoiesis. Slower recovery is seen after double transplantations. The results suggest lasting implications for bone marrow function after autologous transplantation. Bone Marrow Transplantation (2001) 27, 959–966.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. de Vries EGE, de Graaf H, Boonstra A et al. High-dose chemotherapy with stem cell reinfusion and growth factor support for solid tumors Stem Cells 1995 13: 597–606

    Article  CAS  PubMed  Google Scholar 

  2. Niethammer D, Mayer E . Long-term survivors: an overview on late effects, sequelae and second neoplasias Bone Marrow Transplant 1998 21 (Suppl. 2): S61-S63

    Google Scholar 

  3. Rodenhuis S, Richel DJ, van der Wall E et al. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement Lancet 1998 352: 515–521

    Article  CAS  PubMed  Google Scholar 

  4. Antman K, Ayash L, Elias A et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy J Clin Oncol 1992 10: 102–110

    Article  CAS  PubMed  Google Scholar 

  5. Benedetti PP, Greggi S, Scambia G et al. High-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancer Ann Med 1995 27: 133–138

    Article  Google Scholar 

  6. Herrin VE, Thigpen JT . High-dose chemotherapy in ovarian carcinoma Semin Oncol 1999 26: 99–105

    CAS  PubMed  Google Scholar 

  7. Legros M, Dauplat J, Fleury J et al. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results J Clin Oncol 1997 15: 1302–1308

    Article  CAS  PubMed  Google Scholar 

  8. Mandanas RA, Saez RA, Epstein RB et al. Long-term results of autologous marrow transplantation for relapsed or refractory male or female germ cell tumors Bone Marrow Transplant 1998 21: 569–576

    Article  CAS  PubMed  Google Scholar 

  9. Sobecks RM, Vogelzang NJ . High-dose chemotherapy with autologous stem-cell support for germ cell tumors: a critical review Semin Oncol 1999 26: 106–118

    CAS  PubMed  Google Scholar 

  10. Rodenhuis S, de Wit R, de Mulder PH et al. A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission Ann Oncol 1999 10: 1467–1473

    Article  CAS  PubMed  Google Scholar 

  11. Czyzewski EA, Goldman S, Mundt AJ et al. Radiation therapy for consolidation of metastatic or recurrent sarcomas in children treated with intensive chemotherapy and stem cell rescue. A feasibility study Int J Radiat Oncol Biol Phys 1999 44: 569–577

    Article  CAS  PubMed  Google Scholar 

  12. Perentesis J, Katsanis E, DeFor T et al. Autologous stem cell transplantation for high-risk pediatric solid tumors Bone Marrow Transplant 1999 24: 609–615

    Article  CAS  PubMed  Google Scholar 

  13. To LB, Roberts MM, Haylock DN et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants Bone Marrow Transplant 1992 9: 277–284

    CAS  PubMed  Google Scholar 

  14. Domenech J, Roingeard F, Binet C . The mechanisms involved in the impairment of hematopoiesis after autologous bone marrow transplantation Leuk Lymphoma 1997 24: 239–256

    Article  CAS  PubMed  Google Scholar 

  15. Li S, Champlin R, Fitchen JH, Gale RP . Abnormalities of myeloid progenitor cells after ‘successful’ bone marrow transplantation J Clin Invest 1985 75: 234–241

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Mauch P, Hellman S . Loss of hematopoietic stem cell self-renewal after bone marrow transplantation Blood 1989 74: 872–875

    CAS  PubMed  Google Scholar 

  17. Neben S, Hellman S, Montgomery M et al. Hematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents Exp Hematol 1993 21: 156–162

    CAS  PubMed  Google Scholar 

  18. Arnold R, Schmeiser T, Heit W et al. Hemopoietic reconstitution after bone marrow transplantation Exp Hematol 1986 14: 271–277

    CAS  PubMed  Google Scholar 

  19. del Canizo C, Lopez N, Caballero D et al. Haematopoietic damage persists 1 year after autologous peripheral blood stem cell transplantation Bone Marrow Transplant 1999 23: 901–905

    Article  CAS  PubMed  Google Scholar 

  20. Domenech J, Linassier C, Gihana E et al. Prolonged impairment of hematopoiesis after high-dose therapy followed by autologous bone marrow transplantation Blood 1995 85: 3320–3327

    CAS  PubMed  Google Scholar 

  21. Haas R, Witt B, Mohle R et al. Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cell support Blood 1995 85: 3754–3761

    CAS  PubMed  Google Scholar 

  22. Vellenga E, Sizoo W, Hagenbeek A, Lowenberg B . Different repopulation kinetics of erythroid (BFU-E), myeloid (CFU-GM) and T lymphocyte (TL-CFU) progenitor cells after autologous and allogeneic bone marrow transplantation Br J Haematol 1987 65: 137–142

    Article  CAS  PubMed  Google Scholar 

  23. Brice P, Marolleau JP, Pautier P et al. Hematologic recovery and survival of lymphoma patients after autologous stem-cell transplantation: comparison of bone marrow and peripheral blood progenitor cells Leuk Lymphoma 1996 22: 449–456

    Article  CAS  PubMed  Google Scholar 

  24. Siena S, Bregni M, Di NM et al. Durability of hematopoiesis following autografting with peripheral blood hematopoietic progenitors Ann Oncol 1994 5: 935–941

    Article  CAS  PubMed  Google Scholar 

  25. Beguin Y, Baudoux E, Sautois B et al. Hematopoietic recovery in cancer patients after transplantation of autologous peripheral blood CD34+ cells or unmanipulated peripheral blood stem and progenitor cells Transfusion 1998 38: 199–208

    Article  CAS  PubMed  Google Scholar 

  26. Bentley SA, Brecher ME, Powell E et al. Long-term engraftment failure after marrow ablation and autologous hematopoietic reconstitution: differences between peripheral blood stem cell and bone marrow recipients Bone Marrow Transplant 1997 19: 557–563

    Article  CAS  PubMed  Google Scholar 

  27. Amigo ML, del Canizo MC, Caballero MD et al. Factors that influence long-term hematopoietic function following autologous stem cell transplantation Bone Marrow Transplant 1999 24: 289–293

    Article  CAS  PubMed  Google Scholar 

  28. Barbui T, Cortelazzo S, Rossi A et al. Factors for rapid and sustained hematopoietic reconstitution by circulating progenitor-cell transplantation in non-Hodgkin's lymphoma Cancer Chemother Pharmacol 1996 38 (Suppl.): S110–S114

    Article  Google Scholar 

  29. Kiss JE, Rybka WB, Winkelstein A et al. Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation Bone Marrow Transplant 1997 19: 303–310

    Article  CAS  PubMed  Google Scholar 

  30. Rossi A, Cortelazzo S, Bellavita P et al. Long-term haematological reconstitution following BEAM and autologous transplantation of circulating progenitor cells in non-Hodgkin's lymphoma Br J Haematol 1997 96: 620–626

    Article  CAS  PubMed  Google Scholar 

  31. Schwartzberg L, Birch R, Blanco R et al. Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose chemotherapy Bone Marrow Transplant 1993 11: 369–374

    CAS  PubMed  Google Scholar 

  32. Stewart FM, Temeles D, Lowry P et al. Post-5-fluorouracil human marrow: stem cell characteristics and renewal properties after autologous marrow transplantation Blood 1993 81: 2283–2289

    CAS  PubMed  Google Scholar 

  33. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells J Clin Oncol 1995 13: 2547–2555

    Article  CAS  PubMed  Google Scholar 

  34. Dreger P, Kloss M, Petersen B et al. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts Blood 1995 86: 3970–3978

    CAS  PubMed  Google Scholar 

  35. Olivieri A, Offidani M, Montanari M et al. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience Haematologica 1998 83: 329–337

    CAS  PubMed  Google Scholar 

  36. Perez SJ, Caballero MD, Corral M et al. Minimal number of circulating CD34+ cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation Transfusion 1998 38: 385–391

    Article  Google Scholar 

  37. Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients Blood 1995 85: 588–596

    CAS  PubMed  Google Scholar 

  38. Bessman JD, Gilmer PR, Gardner FH . Improved classification of anemias by MCV and RDW Am J Clin Pathol 1983 80: 322–326

    Article  CAS  PubMed  Google Scholar 

  39. Novitzky N, Mohamed R . Alterations in both the hematopoietic microenvironment and the progenitor cell population follow the recovery from myeloablative therapy and bone marrow transplantation Exp Hematol 1995 23: 1661–1666

    CAS  PubMed  Google Scholar 

  40. Darrington DL, Vose JM, Anderson JR et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies J Clin Oncol 1994 12: 2527–2534

    Article  CAS  PubMed  Google Scholar 

  41. Friedberg JW, Neuberg D, Stone RM et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma J Clin Oncol 1999 17: 3128–3135

    Article  CAS  PubMed  Google Scholar 

  42. Kollmannsberger C, Hartmann JT, Kanz L, Bokemeyer C . Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies J Cancer Res Clin Oncol 1998 124: 207–214

    Article  CAS  PubMed  Google Scholar 

  43. Miller JS, Arthur DC, Litz CE et al. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy Blood 1994 83: 3780–3786

    CAS  PubMed  Google Scholar 

  44. Sobecks RM, Le Beau MM, Anastasi J, Williams SF . Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation Bone Marrow Transplant 1999 23: 1161–1165

    Article  CAS  PubMed  Google Scholar 

  45. Traweek ST, Slovak ML, Nademanee AP et al. Myelodysplasia and acute myeloid leukemia occurring after autologous bone marrow transplantation for lymphoma Leuk Lymphoma 1996 20: 365–372

    Article  CAS  PubMed  Google Scholar 

  46. van Leeuwen FE . Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment Baillières Clin Haematol 1996 9: 57–85

    Article  CAS  PubMed  Google Scholar 

  47. Deeg HJ, Witherspoon RP . Risk factors for the development of secondary malignancies after marrow transplantation Hematol Oncol Clin North Am 1993 7: 417–429

    Article  CAS  PubMed  Google Scholar 

  48. del Canizo C, Lopez N, Vazquez L et al. Hematopoietic damage prior to PBSCT and its influence on hematopoietic recovery Haematologica 1999 84: 511–516

    CAS  PubMed  Google Scholar 

  49. Bensinger WI, Longin K, Appelbaum F et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony-stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation Br J Haematol 1994 87: 825–831

    Article  CAS  PubMed  Google Scholar 

  50. Ippoliti C, Przepiorka D, Giralt S et al. Low-dose non-glycosylated rhGM-CSF is effective for the treatment of delayed hematopoietic recovery after autologous marrow or peripheral blood stem cell transplantation Bone Marrow Transplant 1993 11: 55–59

    CAS  PubMed  Google Scholar 

  51. Klumpp TR, Mangan KF, Goldberg SL et al. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial J Clin Oncol 1995 13: 1323–1327

    Article  CAS  PubMed  Google Scholar 

  52. Rowley SD, Piantadosi S, Marcellus DC et al. Analysis of factors predicting speed of hematologic recovery after transplantation with 4-hydroperoxycyclophosphamide-purged autologous bone marrow grafts Bone Marrow Transplant 1991 7: 183–191

    CAS  PubMed  Google Scholar 

  53. van der Wall E, Richel DJ, Holtkamp MJ et al. Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: effect of graft size Ann Oncol 1994 5: 795–802

    Article  CAS  PubMed  Google Scholar 

  54. Spitzer G, Dunphy FR, Petruska PJ et al. Tandem transplants in solid tumors: marrow versus peripheral stem cell transplant: peripheral blood cells as now practiced are not the whole answer J Hematother 1993 2: 363–365

    Article  CAS  PubMed  Google Scholar 

  55. Mauch P, Ferrara J, Hellman S . Stem cell self-renewal considerations in bone marrow transplantation Bone Marrow Transplant 1989 4: 601–607

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank BE Oosterhuis and JS Dijkstra, oncology nurses for their help in patient care and follow-up.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, University Hospital Groningen, Groningen, The Netherlands

    P Nieboer, EGE de Vries, NH Mulder, DTh Sleijfer, PHB Willemse, GAP Hospers, JA Gietema & WTA van der Graaf

  2. Department of Internal Medicine, University Hospital Groningen, Groningen, The Netherlands

    WJ Sluiter

Authors
  1. P Nieboer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. EGE de Vries
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. NH Mulder
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. DTh Sleijfer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. PHB Willemse
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. GAP Hospers
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. JA Gietema
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. WJ Sluiter
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. WTA van der Graaf
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nieboer, P., de Vries, E., Mulder, N. et al. Long-term haematological recovery following high-dose chemotherapy with autologous bone marrow transplantation or peripheral stem cell transplantation in patients with solid tumours. Bone Marrow Transplant 27, 959–966 (2001). https://doi.org/10.1038/sj.bmt.1703030

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703030

Keywords

This article is cited by

Search

Advanced search

Quick links